Key Positives From The 2Q Results
Lower R&D and SG&A expenses cut the 1H operating loss to JPY -1,281M, an improvement of JPY 680M from JPY -1,962M a year earlier. Part of the cost decline came from share-based compensation, which fell from JPY 295M in the prior-year period to JPY 3M. The global Phase 3 trial of nanvuranlat, Beacon-BTC, enrolled its first patient, and Part A is under way in the US. The company also secured a JPY 15B subsidy grant decision from AMED. We view the half as one in which R&D progress and external funding advanced together.
- Lean Cost Base: SG&A was cut to JPY 173M (-65.0% YoY). R&D accounted for 86.4% of operating expenses (our estimate), showing resources concentrated on development.
- Beacon-BTC Enrollment: First patient enrollment and randomization were completed in June 2026. Part A (dose and regimen evaluation) is progressing smoothly in the US (company disclosure).
- AMED Subsidy Secured: The grant was approved at the full requested amount of JPY 15B, and the subsidized program began on 10/29. Phase 3 Part A costs can now be partly funded externally.
- JPH034 Progress Rate: The US Phase 1 trial is on track. The company signed a non-binding Term Sheet with a European biotech company covering worldwide rights, excluding Japan, South Korea, Taiwan and ASEAN.
- Broadening Pipeline: First dosing in the investigator-initiated trial combining nanvuranlat with ICIs in first-line therapy (JON-2404-B) took place in July. A candidate compound has also been identified for the next-generation LAT1 inhibitor.
Key Concerns From The 2Q Results
Operating cash outflow widened to JPY -1,462M from JPY -1,126M a year earlier. Cash and cash equivalents fell to JPY 2,931M (-34.2% vs. prior fiscal year-end). The full-year plan implies a larger loss in 2H. Cash runway will therefore depend on when subsidy funds are received and whether partnership upfront payments materialize.
- No Subsidy Income: The prior-year period included JPY 328M in subsidy income, which did not recur. Non-operating income fell to JPY 21M (-94.4% YoY). As a result, recurring loss narrowed by only JPY 272M, less than the JPY 680M improvement at the operating level.
- Rising Burn Rate: The standalone 2Q operating loss was approx. JPY 711M, up from approx. JPY 570M in 1Q (our estimate). Expense run-rate is climbing as clinical trials ramp up.
- FX Exposure: The company holds JPY 1,964M in foreign-currency MMFs and booked an FX loss of JPY 62M. Holding foreign currency to fund overseas payments introduces currency volatility into the P&L.
- Term Sheet Risk: The JPH034 Term Sheet is not legally binding, except for certain provisions. A definitive agreement may not be reached, depending on due diligence results and other factors (company disclosure).
- Drawing Down IPO Proceeds: Subsidy repayments resulted in an outflow of JPY 50M. Financing CF was just JPY 21K, and the company has moved into drawing down funds raised at the IPO.
Focus Areas / Items To Monitor Going Forward
- AMED Subsidy Timing: When the JPY 15B AMED subsidy will be received and booked. Full-year guidance was left unchanged after weighing higher R&D costs against subsidy income. The balance between 2H operating and recurring results is the key point to watch.
- Beacon-BTC Enrollment: Patient enrollment pace in Beacon-BTC Part A and progress on expansion into Japan and South Korea. Timing of the move to Part B is the key indicator of nanvuranlat's approval timeline.
- JPH034 Definitive Agreement: Whether a definitive license agreement for JPH034 is signed, and on what economic terms. Upfront and milestone payments would significantly ease funding constraints.
- Year-by-year receipt and booking schedule for the JPY 15B AMED subsidy, and its classification in the income statement
- Timeline for negotiations toward a definitive JPH034 agreement, and the expected consideration structure (upfront, milestones, royalties)
- Cash runway based on cash and cash equivalents of JPY 2,931M, and policy on additional fundraising
- Expected completion timing for Beacon-BTC Part A, and the scale of additional costs from expansion into Japan and South Korea
- Size of foreign-currency MMF holdings and FX risk management policy
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Operating Revenue | - | - |
| Total Operating Expenses | JPY 1,281M | -34.7% |
| └R&D Expenses | JPY 1,107M | -24.4% |
| └SG&A | JPY 173M | -65.0% |
| Operating Income | JPY -1,281M | Prior year JPY -1,962M |
| Non-Operating Income | JPY 21M | -94.4% |
| └Subsidy Income | - | Prior year JPY 328M |
| Non-Operating Expenses | JPY 62M | Prior year JPY 10M |
| └FX Loss | JPY 62M | Prior year - |
| Recurring Profit | JPY -1,323M | Prior year JPY -1,595M |
| Extraordinary Income (Gain on Reversal of Stock Acquisition Rights) | JPY 7M | Prior year JPY 177M |
| Interim Net Income | JPY -1,317M | Prior year JPY -1,428M |
| EPS | JPY -73.15 | Prior year JPY -123.22 |
- Below-the-Line Drag: Operating loss narrowed by JPY 680M, but subsidy income and gains on reversal of stock acquisition rights fell away. As a result, the interim net loss narrowed by only JPY 111M.
- EPS Dilution Effect: The smaller loss per share partly reflects the higher average share count (11,596,305 → 18,003,953 shares). The increase stems from shares issued at the March 2026 IPO.
Performance By Business Segment
The company operates a single drug discovery segment and booked no operating revenue. R&D expenses account for the bulk of costs and are directed mainly to the global Phase 3 trial of nanvuranlat and the US Phase 1 trial of JPH034.
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| Drug Discovery | - | - | JPY -1,281M | Prior year JPY -1,962M | - |
- Nanvuranlat (Second-Line Biliary Tract Cancer): Beacon-BTC completed first patient enrollment in June, and Part A is progressing smoothly in the US. The JPY 15B AMED subsidy strengthens funding for the Phase 3 program.
- Nanvuranlat (Indication Expansion): First dosing took place in July in the investigator-initiated ICI combination trial JON-2404-B. A post-hoc analysis paper on domestic clinical data was published in Cancers in August.
- JPH034 (Secondary Progressive Multiple Sclerosis): The US Phase 1 trial is on track, and a Term Sheet was signed with a European company. In October, the company established a Business Development Department to drive partner negotiations.
- Operating Revenue: No revenue was booked again this 1H. Monetization through license income depends on signing a definitive JPH034 agreement.
- KRAS-Mutant Colorectal Cancer: The investigator-initiated trial remains in preparation. Timing of clinical entry is an item to monitor.
Progress Versus Full-Year Guidance
Operating loss stood at 45.1% of the full-year plan, below the 52.9% recorded in the prior-year period (1H JPY -1,962M / full-year actual JPY -3,710M). Backing out from the plan implies a 2H operating loss of JPY 1,560M, a larger cost base than the JPY 1,281M in 1H (our estimate). Given the wider standalone 2Q loss, 1H progress is within plan.
| Item | Value (2Q Cumulative) | Full-Year Forecast | Progress |
|---|---|---|---|
| Operating Revenue | - | - | - |
| Operating Income | JPY -1,281M | JPY -2,841M | 45.1% |
| Recurring Profit | JPY -1,323M | JPY -2,841M | 46.6% |
| Net Income | JPY -1,317M | JPY -2,842M | 46.3% |
| EPS | JPY -73.15 | JPY -158.08 | 46.3% |
Changes To Guidance
Full-year guidance (announced 2026/5/14) was left unchanged. The company weighed higher R&D costs from advancing clinical development against subsidy income following the AMED grant decision. Management stated it will announce any revision if changes in costs or subsidy income from future development progress make one necessary.
Commentary On Shareholder Returns
The annual dividend forecast was maintained at JPY 0.00, and the company remains non-dividend-paying. There were no share buybacks. Effective 2026/8/11, the company reduced capital stock by JPY 1,952M and capital reserve by JPY 513M to offset accumulated losses of JPY 2,466M carried forward through the prior fiscal year-end.
Financial Position
The company has no interest-bearing debt and maintains a sound balance sheet with an equity ratio of 82.5%. However, upfront development spending reduced cash on hand by roughly one-third over the half. Securing subsidies and partnership income will now determine the direction of its finances.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Cash and Cash Equivalents | JPY 2,931M | -34.2% vs. prior fiscal year-end |
| └Cash and Deposits | JPY 966M | -78.3% vs. prior fiscal year-end |
| └Securities (Foreign-Currency MMF) | JPY 1,964M | JPY 1M at prior fiscal year-end; held to fund overseas payments (company disclosure) |
| Total Assets | JPY 3,365M | -29.3% vs. prior fiscal year-end |
| Total Liabilities | JPY 295M | -22.8% vs. prior fiscal year-end; includes accrued expenses of JPY 154M |
| Shareholders' Equity | JPY 2,776M | -31.7% vs. prior fiscal year-end |
| Stock Acquisition Rights | JPY 294M | JPY 312M at prior fiscal year-end |
| Interest-Bearing Debt | JPY 0M | No borrowings recorded |
| Operating CF | JPY -1,462M | Prior year JPY -1,126M |
| EBITDA | JPY -1,281M | Operating income + depreciation (none recorded this 1H); our estimate |
| Metric | Value | Notes |
|---|---|---|
| Debt/Equity | 0.00x | Debt-free; our estimate |
| Equity Ratio | 82.5% | 85.4% at prior fiscal year-end; company disclosure |
Disclosures Released Alongside The Earnings Announcement
- 2026/11/11The company announced an FX loss booked as a non-operating expense. The FX loss in the interim income statement was JPY 62M, and we view foreign-currency holdings as a source of earnings volatility to watch (Notice Regarding Recording of Non-Operating Expenses (FX Loss))
Major Announcements During The Quarter
- 2026/09/25Signed a non-binding Term Sheet for JPH034 with a European biotech company covering worldwide rights, excluding Japan, South Korea, Taiwan and ASEAN
- 2026/10/05Beacon-BTC was selected for AMED's Global R&D Support Program for Intractable and Rare Disease Treatments
- 2026/10/14Decided to expand Beacon-BTC Part A into Japan and South Korea, widening the geographic base for patient enrollment
- 2026/10/15Established a Business Development Department to drive partnerships for pipeline assets, strengthening the setup for JPH034 partner negotiations
- 2026/10/30The AMED subsidy was approved at the full requested amount of JPY 15B, and the subsidized program began on 10/29
Large-Shareholding Filings / Material Proposals Over The Past Year
- JIC Venture Growth Investments: New → 11.3% (2026/03/25) - Pure investment
- Eight Roads Ventures Japan II L.P.: New → 10.9% (2026/03/25) - Pure investment
- Newton Biocapital I Pricaf Privée de Droit Belge: New → 6.9% (2026/03/25) - Pure investment
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.